• 2025-03 - While watching TV, I scratched my neck and discovered a lump which didn't seem to belong.
• 2025-03-25 - Left neck lymph node biopsy collected.
• 2025-03-27- Final Diagnosis reported: Metastatic tumor, most consistent with metastatic adenocarcinoma of pulmonary origin (TTF-1 and napsin A positive).
• 2025-03-28- XR Chest showed left lower lobe consolidation, atelectasis, and small left pleural effusion.
• 2025-03-28- CT Chest Abdo Pelvis w/ Contrast identified a 47 x 31 x 24 mm left lower lobe mass (primary lung neoplasm), metastatic adenopathy, and findings suspicious for pleural deposits; No evidence of extrathoracic metastatic disease in the abdomen/pelvis.
• 2025-04-09 - PET/CT FDG Whole Body performed; confirmed extensive hypermetabolic disease, including: left lower lobe mass (3.3x4.7 cm), pleural metastases, widespread lymphadenopathy, and osseous metastatic disease (left pedicle of L2).
• 2025-04-15 - Oncology Medical Consult; diagnosis confirmed as metastatic lung adenocarcinoma; baseline molecular biomarkers: PD-L1 <1%, ALK negative; Focus panel pending.
• 2025-04-22 - Electrocardiogram 12 Lead STAT performed; noted Sinus Bradycardia and Voltage Criteria for Left Ventricular Hypertrophy.
• 2025-04-23 - Molecular Genetics Report reported EGFR:c.2573T>G, p. Leu858Arg (L858R) mutation.
• 2025-05-01 - Osimertinib single agent therapy initiated.
• 2025-05-01 - MRI Head w/ Contrast performed; No cranial metastasis identified (Completing staging).
• 2025-05-27 - Blood collected; Platelets measured at (Low).
• 2025-05-27 - Oncology Follow-up (1 month post-osimertinib); patient tolerating treatment well; left supraclavicular lymphadenopathy is getting softer; labs showed lowered platelets ().
• 2025-05-29 - Cardiac Ultrasound performed; showed Normal LVEF (57%), Left Atrium severely dilated, and a trivial pericardial effusion (new compared to 2020).
• 2025-06-18 - Blood collected; Platelets measured at .
• 2025-06-18 - XR Chest performed; imaging findings were stable compared to April 22, 2025.
• 2025-06-24 - Oncology Follow-up (2 months post-osimertinib); confirmed good tolerance; patient feels neck nodes and breathing have improved.
• 2025-07-29 - CT Chest Abdo Pelvis w/ Contrast performed; demonstrated apparent improvement/response to treatment, including reduction of left lower lobe mass (to 36x22 mm, previously 47x33 mm) and improved mediastinal lymphadenopathy.
• 2025-07-29 14:59 - CT Head performed; No evidence of intracranial metastases.
• 2025-08-12 14:09 - Oncology Follow-up (approx. 4 months post-Osimertinib); confirmed tolerance, managing mild diarrhea/paronychia; left cervical lymph node size further improved (0.5-1 cm mobile node).
• 2025-10- Patient turned 56 years old.
• 2025-10-17 - PET/CT FDG Whole Body (Restaging) performed; showed significant metabolic improvement compared to April PET scan; LLL nodule now approximately 17 mm (SUVmax 3.8); near-complete left lower-lobe collapse secondary to bronchial obstruction noted.
• 2025-10-29 - CT Neck Chest Abdo Pelvis w/ Contrast performed; showed disease was stable compared to July 2025 scan; incidental nonocclusive pulmonary emboli (PE) found in the segmental and subsegmental right lower lobe pulmonary arteries.
• 2025-10-29 - Progress Note documented incidental PE finding; patient asymptomatic; Apixaban (anticoagulant) initiated.
No comments:
New comments are not allowed.